Nurix Therapeutics (NRIX) said Monday that the US Food and Drug Administration has granted orphan drug designation to the company's experimental drug, bexobrutideq, for treating Waldenstrom macroglobulinemia, a type of blood cancer.
The company said the drug is currently being evaluated in a phase 1 trial for adults with relapsed or refractory B-cell malignancies.
The US health agency's orphan drug designation program supports the development of treatments for rare diseases, impacting fewer than 200,000 individuals in the US, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.